AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 19 - (NewsRx.com & NewsRx.net) -- by Roxanne Nelson, staff medical writer - Variations in T-cell responses, both in the active disease phase and after healing of leishmaniasis, may be relavent in helping determine patient prognosis as well as in the development of preventive vaccines, say researchers in Brazil.
Serigio Coutinho, Laboratorio de Imunidade Celular e Humoral at the Instituto Oswaldo Cruz in Brazil, and colleagues, examined the T-cell immune responses in cases of both cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML). Patients were assessed while their disease was active, when therapy was completed, and then from 1 to 17 years after their cure.
The investigators observed that there were higher amounts of CD4[superscript]+ T cells, as compared with CD8[superscript]+ T cells, in cases of active ML and CL. As healing took place in CL patients, there was a decrease of CD4[superscript]+ with an accompanying increase of CD8[superscript]+. This immune response was also observed in ML patients but only after prolonged treatment.
"Long-term follow-up of patients with CL showed a positive CD4[superscript]+/CD8[superscript]+ ratio as observed during the active disease although the percentages of these T cell subsets were significantly lower," explained the researchers.
No significant differences were observed between gamma interferon (IFN-(gamma)) and interleukin-5 (IL-5) levels in the CL patients over the course of the study. In contrast, both higher IFN-(gamma) and IL-5 levels were observed in active ML cases. In the long term, patients who recovered from ML presented with a high level of IFN-(gamma) and significant decrease of IL-5. IL-4 was present only while the disease was in an active phase ...
Source: HighBeam Research, Observations in T cell response may help develop immunotherapy.(Brief...